Recurrent small cell lung cancer: update

Abstract

Small cell lung cancer continues to recur and claim the lives of most of its victims. Thus, management of the patient with recurrent disease remains an active area of research. This review provides an update of clinical research experience over the past decade with relatively new conventional cytotoxins in this setting, such as the topoisomerase I inhibitors and the taxanes. Additionally, novel molecular targeted approaches with specific relevance for small cell lung cancer are discussed.